Abstract:We investigated type 2 diabetes (T2D) genetic susceptibility in a multi-ethnic meta-analysis of 228,499 cases and 1,178,783 controls in the Million Veteran Program (MVP) and other biobanks. We identified 558 autosomal and 10 X-chromosome T2D-associated variants, of which 286 autosomal and 7 X-chromosome variants were previously unreported. Ancestry-specific analyses identified 25 additional novel T2D-susceptibility variants. Transcriptome-wide association analysis detected 3,568 T2D-associations with T2D-colocalized genetically predicted gene expression of 804 genes in 52 tissues, of which 687 are novel. Fifty-four of these genes are known to interact with FDA-approved drugs and chemical compounds. T2D polygenic risk score was strongly associated with increased the risk of T2D-related retinopathy, and additionally showed evidence for association with chronic kidney disease (CKD), neuropathy, and peripheral artery disease (PAD). We investigated the genetic etiology of T2D-related vascular outcomes in the MVP and observed statistical SNP-T2D interactions at 13 variants, including 3 for coronary heart disease, 1 for PAD, 2 for stroke, 4 for retinopathy, 2 for CKD, and 1 for neuropathy. Our findings may identify potential novel therapeutic targets for T2D and genomic pathways that link T2D and its vascular outcomes. ### Competing Interest Statement None of the sponsors of the following authors had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. D.S. has received support from the British Heart Foundation, Pfizer, Regeneron, Genentech, and Eli Lilly pharmaceuticals. L.S.P. has served on Scientific Advisory Boards for Janssen, and received research support from Abbvie, Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, Pfizer, Kowa, and the Cystic Fibrosis Foundation. L.S.P. is a cofounder, officer, board member, and stockholder of a diabetes management-related software company names Diasyst, Inc. S.L.D. has received research grant support from the following for-profit companies through the University of Utah or the Western Institute for Biomedical Research (VA Salt Lake City's affiliated non-profit): AbbVie Inc., Anolinx LLC, Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG, and PAREXEL International Corporation. ### Funding Statement This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration and was supported by award no. MVP000. This publication does not represent the views of the Department of Veterans Affairs, the US Food and Drug Administration, or the US Government. This research was also supported by funding from: the Department of Veterans Affairs award I01-BX003362 (P.S.T. and K.M.C) and the VA Informatics and Computing Infrastructure (VINCI) VA HSR RES 130457 (S.L.D) B.F.V. acknowledges support for this work from the NIH/NIDDK (DK101478), the NIH/NHGRI (HG010067) and a Linda Pechenik Montague Investigator award. K.M.C, S.M.D, J.M.G, C.J.O, L.S.P, and P.S.T. are supported by the VA Cooperative Studies Program. S.M.D. is supported by the Veterans Administration [IK2-CX001780]. D.K. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health [T32 HL007734]. L.S.P. is supported in part by VA awards I01-CX001025, and I01CX001737, NIH awards R21DK099716, U01 DK091958, U01 DK098246, P30DK111024, and R03AI133172, and a Cystic Fibrosis Foundation award PHILLI12A0. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The full summary level association data from the trans-ancestry meta-analysis from this report will be available through dbGAP (accession codes will be available before publication).

Supplemental Data from Identification of a Genomic Region Between <i>slc29a1</i> and <i>hsp90ab1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Abstract 7160: Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Loci influencing blood pressure identified using a cardiovascular gene-centric array (Correction to Ganesh et al. 22 (8): 1663)

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension

Abstract 040: Comparative Genomic Analysis and Functional Insights for Blood Pressure-Associated Single Nucleotide Polymorphisms

Abstract 076: the Blood Pressure-associated Non-coding Single Nucleotide Polymorphism Rs28451064 Influences Gene Expression in Human Endothelial Cells

Abstract 478: Biological Pathways Mediating the Effect of a 1.37 Mbp Genomic Region on Salt-Induced Hypertension in the SS Rat

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825

Abstract P367: Cross-Species Epigenomic Maps of Intergenic Loci for Hypertension and Blood Pressure

Characterization of Biological Pathways Associated with a 1.37 Mbp Genomic Region Protective of Hypertension in Dahl S Rats

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)

Abstract 2037: A Discovery Study to Identify Clinical and Genetic Risk Factors for Bevacizumab (Bev)-Related Gastrointestinal (GI) Hemorrhage (HEM) in Metastatic Castration-Resistant Prostate Cancer (mcrpc) Patients (pts) Treated on CALGB 90401 (Alliance)

Hypertension in Dahl S Rats with a 1.37 Mbp Genomic Region Protective of Characterization of Biological Pathways Associated

Genome-wide Maps of Human Kidney Proximal Tubules and Thick Ascending Limbs of Henle Reveal an Enrichment for Human Blood Pressure Associated Polymorphisms

Genome‐wide Association Studies of Survival in 1520 Cancer Patients Treated with Bevacizumab‐containing Regimens

Discovery of 318 novel loci for type-2 diabetes and related micro- and macrovascular outcomes among 1.4 million participants in a multi-ethnic meta-analysis

Abstract 8: Polygenic Resistance to Blood Pressure Treatment and Stroke Risk

Gene-centric Meta-Analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-related Loci.

Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis

Supplemental Data from Identification of a Genomic Region Between &lt;i&gt;slc29a1&lt;/i&gt; and &lt;i&gt;hsp90ab1&lt;/i&gt; Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)